Screener / SEC EDGAR /CIK 0000883984 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

ICU Medical Inc ICUI

Compare with peers Embed
What it said it expected, against what it reported

No target with a reported result yet

Releases of the last 3 years

The numbers ICUI said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $400.00M to $430.00M release Feb 19, 2026
Raised $415.00M to $435.00M release Nov 5, 2026
– No standard number
The company's words
For the fiscal year 2026, the Company expects adjusted EBITDA to be in the range of $400 million to $430 million, and adjusted EPS to be in the range of $7.75 to $8.45. release Feb 19, 2026
The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00. release Nov 5, 2026
Net income
Fiscal 2026
Given $73.00M to $83.00M release Nov 5, 2026
– Not reported yet
The company's words
The Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. release Nov 5, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $7.75 to $8.45 release Feb 19, 2026
Raised $8.60 to $9.00 release Nov 5, 2026
– No standard number
The company's words
Fiscal Year 2026 Guidance … For the fiscal year 2026, the Company expects adjusted EBITDA to be in the range of $400 million to $430 million, and adjusted EPS to be in the range of $7.75 to $8.45. release Feb 19, 2026
The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00. release Nov 5, 2026
Diluted EPS
Fiscal 2026
Given $2.89 to $3.29 release Nov 5, 2026
– Not reported yet
The company's words
The Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. release Nov 5, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $395.00M to $425.00M release Feb 27, 2025
– No standard number
The company's words
For the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. release Feb 27, 2025
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $6.55 to $7.25 release Feb 27, 2025
– No standard number
The company's words
Fiscal Year 2025 Guidance … For the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. release Feb 27, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $330.00M to $370.00M release Feb 27, 2024
– No standard number
The company's words
For the Fiscal Year 2024, the Company expects adjusted EBITDA to be in the range of $330 million to $370 million, and adjusted diluted EPS to be in the range of $4.40 to $5.10. release Feb 27, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $4.40 to $5.10 release Feb 27, 2024
– No standard number
The company's words
Fiscal Year 2024 Guidance … For the Fiscal Year 2024, the Company expects adjusted EBITDA to be in the range of $330 million to $370 million, and adjusted diluted EPS to be in the range of $4.40 to $5.10. release Feb 27, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.